Trial Search Results

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Protocol Title: Randomized open label study comparing the metabolic control of first Kidney Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral as part of a ATG induction, prednisone free and blood monitored Cellcept immunosuppressive regimen.

PURPOSE This is a single center medical research study to analyze post-transplant kidney recipients with pre-existing type 2 diabetes managed according to the recommended American Diabetes Association (ADA) guidelines. Prograf (Tac) and Neoral (CSA) are the two main medications to prevent rejection after transplantation. However, they may contribute to poorer diabetes control. The purpose of the study is to compare the effects of Prograf and Neoral on the control of Diabetes after kidney transplantation. In addition, all participants in this study will receive Thymoglobulin (anti-lymphocyte globulin) at the time of transplantation instead of long term prednisone (steroids).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Cyclosporin
  • Drug: Tacrolimus
  • Behavioral: 'Diabetes Education / Management'


Phase 4


Inclusion Criteria:

Inclusion Criteria

   1. Patient is a recipient of a first cadaveric kidney, or a kidney living donor
   mismatched (at least one mismatch.)

   2. Patient is a minimum of 18 years of age at the time of transplant.

   3. Patient has type 2 non-insulin dependent diabetes.

   4. Patient or legal guardian has signed and dated an Ethics Committee-approved informed
   consent document and is willing and able to follow study procedures.

   5. If female and is childbearing potential, patient has a negative pregnancy test and
   utilizes adequate contraceptive methods.

Exclusion Criteria

   1. Recipients of a transplant graft from a donor age 65 and older.

   2. Recipient of a multi-organ transplant.

   3. Patients who are being re-transplanted will not be eligible for study.

   4. Patients who have lost a previous graft to rejection less than one year from

   5. Patient has any form of substance abuse, psychiatric disorder, or a condition in the
   opinion of the investigator, may invalidate communication with the investigator.

   6. PRA > 30%

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Stephan Busque, MD
Not Recruiting